Sanofi Pasteur delivers first 2015-2016 seasonal flu vaccines in U.S.
The shipment received the approval of the U.S. Food and Drug Administration (FDA) before being released.
"Influenza is a serious respiratory illness that is easily spread and can lead to severe complications involving the heart, lung, endocrine and other organ systems, potentially leading to death," David P. Greenberg, M.D., vice president, Scientific & Medical Affairs, and chief medical officer, Sanofi Pasteur U.S., said. "Vaccination is important for high-risk age groups, including children and older adults. For older adults, vaccination is particularly important given their susceptibility to influenza and its complications due to an age-related weakening of the immune system."
The delivery comprises of more than 65-million seasonal influenza vaccine doses. Beginning in July, these doses, which were manufactured by Sanofi Pasteur, will be distributed throughout pharmacies and healthcare providers in the U.S. The deliveries will continue as the 2015-2016 influenza season progresses.
"Sanofi Pasteur is committed to helping people fight influenza by offering a broad range of vaccines for patients across multiple age groups," Greenberg said. "Patients should speak to their healthcare providers to determine which influenza vaccine option is most appropriate."